Although the high expression of PD-L1 in the cancer tissue region is associated with immune evasion and poor prognosis in CRC patients [29,30,31,32], the mechanisms of unresponsiveness and resistance to PD-1/PD-L1 blockade therapies are largely unknown. This evidence concerns the gene PDCD1 and cancer.